Document is current
Any future updates will be listed below
-
Authors
Sandmann, Abel Clemens Adriaan https://orcid.org/0009-0008-9744-8544
Kempeneers, Marinus Abraham https://orcid.org/0000-0003-2860-4458
van den Berg, René https://orcid.org/0000-0002-8791-8791
Vandertop, William Peter https://orcid.org/0000-0001-5417-0265
Verbaan, Dagmar https://orcid.org/0000-0002-9212-5470
Coutinho, Jonathan M. https://orcid.org/0000-0002-8284-982X
- License Information
-
More Information
Article History
Received: 7 August 2024
Revised: 30 September 2024
Accepted: 5 October 2024
First Online: 12 December 2024
Declarations
:
: JMC received financial support from the Dutch Heart Foundation, Medtronic, Bayer and Boehringer (all fees were paid to his employer), and is co-founder and shareholder of TrianecT. RvdB has a non-personal hospital consultancy at Johnson & Johnson (CERENOVUS). All other authors declare that there are no relevant financial or non-financial interests to disclose.
: This study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. This study was waived for ethical approval by the Institutional Review Board of the Amsterdam UMC because it did not fall under the scope of the Medical Research Involving Human Subjects Act (WMO).
: All patients provided written informed consent for the use of clinical data and data derived from the questionnaire.
